Page 10 - Tanmay Tiwary

PB Fintech share zooms 5% on robust Q2 insurance growth; buy, sell or hold?

PB Fintech shares rose after the company reported a strong September quarter (Q2FY26) performance, driven by robust growth in its insurance segment.

Coal India Q2 hit by weak volumes, high costs; brokerages split on outlook

Motilal Oswal, however, remained upbeat on Coal India, calling the earnings a 'big miss due to high costs' but maintaining its 'Buy' rating with a target price of ₹440.

APL Apollo fires on all cylinders; what's next for the stock? Find out here

Analysts at Nuvama noted that APL Apollo launched its new 'SG Premium' product line at around ₹49,500 per tonne to counter competition from secondary steel players.

Maruti Suzuki Q2 Preview: What to expect from India's largest carmaker?

Maruti Suzuki Q2 Preview: Maruti Suzuki India will likely announce its September quarter results on October 31, 2025.

Robust Q2, GST tailwind lift M&M Fin to 52-wk high; analysts raise targets

While earnings came in ahead of expectations for M&M Financial Services, analysts remain watchful of persistently high credit costs and moderation in asset growth.

Strong Q2, EV gains power bullish view on TVS Motor Company; targets raised

The Street expects TVS Motor's consistent outperformance, new launches, and EV traction to sustain earnings momentum, even as some brokerage houses flag valuation concerns.

Top 3 factors powering Groww's dominance in retail broking; find out here

Groww's active client base has grown at a remarkable FY21-25 compound annual growth rate (CAGR) of 101.7 per cent, sharply outpacing the industry's 27 per cent and AngelOne's 48.3 per cent.

SRF's chemicals biz leads Q2 growth; analysts stay bullish; check targets

Brokerages maintained a positive stance on SRF, highlighting continued margin strength, steady volume growth, and the company's strategic capex expansion.

Hyundai India Q2 preview: Margins seen rising on richer mix, cost control

Hyundai Motor India will release its September quarter of financial year 2026 (Q2FY26) results on October 30, 2025.

Target @₹7,000: IndiGo set to fly higher as Anand Rathi initiates with Buy

Anand Rathi believes IndiGo's disciplined low-cost structure, commanding market share, and strategic global expansion make it a long-term compounding story in Indian aviation.

PNB Housing delivers steady Q2; analysts bullish on growth, margin outlook

On the bourses around 9:30 AM, PNB Housing share was trading flat at ₹927.45 apiece. By comparison, BSE Sensex was trading marginally higher at 84,792.25 levels.

Sona BLW's diversified growth drivers impress brokerages; Nomura ups target

Nomura said Sona's ability to add orders across segments despite a weak EV backdrop reflects its growing engineering depth.

InCred Equities upgrades Tata Steel to 'Add'; stock hits fresh 52-week high

On the bourses, Tata Steel shares rose as much as 1.91 per cent to hit a fresh 52-week high of ₹177.85 per share.

Steady growth, firm margins lift SBI Life to 52-wk high; analysts keep Buy

At 10 AM, SBI Life share price continued to trade in the northward direction, up 3.37 per cent at ₹1,902.60 per share. By comparison, BSE Sensex was trading 0.57 per cent higher at 84,695.60 levels.

Coforge gains 6% as analysts turn bullish after Q2, see up to 36% upside

On the bourses, Coforge share price zoomed up to 5.98 per cent to hit an intraday high of ₹1,866 per share post Q2 results.

Brokerages see near-term upside in Dr Reddy's on Semaglutide, ex-US growth

Dr Reddy's Laboratories reported a consolidated Q2FY26 net profit of ₹1,437.2 crore, up 14 per cent Y-o-Y from ₹1,255.3 crore, with sequential growth largely flat.

Double whammy hits Colgate: GST cuts, competition weigh on Q2 sales

Analysts largely agree that the toothpaste major's volumes and revenue were hit by a 'double whammy' of GST rate cuts and intensifying competition, with limited signs of a near-term recovery.

TVS Motor Q2 preview: PAT may zoom upto 45% YoY; other key estimates inside

On the bourses around 11:00 AM, TVS Motor share price was trading 0.27 per cent higher at ₹3,609.65 per share. In comparison, BSE Sensex was trading 0.33 per cent lower at 84,279.72 level.

Nuvama retains 'Hold' on Cipla, raises target after Eli Lilly diabetes deal

Cipla- Eli Lilly deal: Tirzepatide is a prescription drug used for managing type 2 diabetes and aiding weight loss in adults who are obese or overweight.

3 reasons why Axis Securities slashed IndiaMART Intermesh target price

IndiaMART Intermesh outlook: Analysts remain optimistic about the broader digital B2B marketplace opportunity and believes IndiaMART is well-placed to sustain growth as MSME digitisation deepens.